David Crean

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.

Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.

Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOM’s Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.

Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.

Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.

Larry Weis

Nicholas Monsul M.D., F.A.C.S.

Dr. Monsul was born in Philadelphia and graduated from Drexel University.  He completed his medical degree at Hahnemann University, Drexel University College of Medicine.  His ophthalmology residency at Yale University was followed by fellowship programs at The Johns Hopkins Hospital, The Wilmer Eye Institute and Allegheny General Hospital in Pittsburgh.  He moved to Florida in 2003.  Throughout his career and education, he has been involved in basic science research with a particular interested in neural regeneration and neuronal cell death.  In addition to his roles at Quorum Innovations where he is actively involved in the research program, he is a surgeon with a busy practice in the Hawthorne Clinic and Research Center.

Ronie Schmelz

Travis Whitfill

Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.

His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States. 

Raymon uit de Bulten

Allison Krebs Bensch

Allison Krebs-Bensch, a graduate of Vanderbilt University, has been intrinsically involved in her family’s pharmaceutical business, US Pharmaceutical Corporation, since graduating.  Rolling up her sleeves, Allison dove into learning every aspect of the business from Sales to R & D, before eventually taking over the responsibilities of CEO. 

Allison’s accomplishments include being listed as an inventor on patents for Improved Toleration of Iron Supplement Compositions.  Additionally, she has developed, progressive & pending, patented formulations utilizing new probiotic strains for various applications of use.  Most recently, she has co-founded and is CEO of a start-up probiotic skin care company, BeBe and Bella.  This company specializes in delivering probiotics and their fermented filtrates, both orally and topically, for improved natural beauty.   As co-founder, Allison has been invited to be  a Speaker at several symposiums related to the science behind probiotics.

Cecile Kalem

Elsa Jungman

Kelly Haas PhD

Kelly N. Haas is a postdoctoral skin microbiome researcher at the University of California Davis Medical Center (Dermatology) and California State University Sacramento (Biology). Her PhD was completed at the University of Massachusetts under Jeffrey Blanchard, where she focused on the gut-associated family Lachnospiraceae, including

discovering, characterizing, and sequencing several novel bacteria. She is especially interested in the microbial ecology and feedbacks between the microbiome and the host, as well 

as translational research in inflammatory skin conditions like acne, rosacea, eczema, and alopecia. Much of her postdoctoral work has focused on methods development and 

optimization for the skin microbiome, allowing more accurate capture of the human skin microbiome profile.

Philip Ludwig